P-1464. Nasopharyngeal Colonization in South Texas Children less than 6 Years of Age with or without Lower Respiratory Tract Infections

Abstract Background Recently, two new pneumococcal conjugate vaccines (PCV15 and PCV20) were introduced in the United States (US). We sought to define the current nasopharyngeal (NP) colonization prevalence and serotype distribution of pneumococci (SPN) obtained from children seeking care at Texas Children’s Hospital, Houston, TX, US, for respiratory infections and to report their PCV status.Table 1.Demographic and clinical characteristics of the study population* 143 children were either recorded as unvaccinated (n=12), or their parents expressed uncertainty regarding vaccination status and their PCV vaccine records were not available.**Respiratory syncytial virusFigure 1.Serotype distribution of nasopharyngeal isolates from children 2 µg/ml (i.e. non-susceptible by Clinical Laboratory and Standards Institute (CLSI) guidelines for IV treatment of non-CNS SPN infections). RSV was the most common respiratory virus identified. Among 818 children with vaccination data and at least one dose of PCV, 724 were vaccinated with one or more doses of PCV13, 42 (5.1%) had received at least one dose of PCV15, 152 (18.6%) had received at least one dose of PCV20. Twelve were reported unvaccinated. Conclusion Initial data indicate serotypes 11A and 15B (both contained in PCV20, as well as 23B and 35B (not contained in any licensed pediatric PCV) are common colonizers among children age < 6 years old in Houston. All but one isolate was penicillin susceptible for treating non-CNS infections. Disclosures Kristina G. Hulten, PhD, Pfizer: Grant/Research Support Andrea T. Cruz, MD, MPH, Pfizer: Grant/Research Support Lindsay Grant, PhD, MPH, Pfizer: Employee|Pfizer: Stocks/Bonds (Private Company) Adriano Arguedas, Medical director, Pfizer employee: employee|Pfizer employee: Stocks/Bonds (Public Company) Maria J. Tort, PhD, Pfizer, Inc: Stocks/Bonds (Public Company) Ashley Miller, MA, CCRP, Pfizer: Stocks/Bonds (Public Company) Alejandro D. Cane, MD, PhD, Pfizer Inc.: All authors are employees of Pfizer Inc. and may hold stock and/or stock options of Pfizer Inc. Sheldon L. Kaplan, MD, Pfizer: Grant/Research Support